Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 5,060 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Chronic Constipation, Functional Constipation
Interventions: Placebo Capsule, YKP10811 Drug Product Capsule; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Disorder Related to Renal Transplantation
Interventions: Curcumin, Placebo; Dietary Supplement · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Obesity
Interventions: Lactobacillus Rhamnosus GG, Placebo; Dietary Supplement
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lupus Nephritis
Interventions: Voclosporin, Placebo Oral Capsule; Drug
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Body Weight Changes
Interventions: Meal replacement shake, Multivitamin and mineral capsules, Fish oil with sesame lignans and olive extract softgel, Prebiotic Chewable tablet, Clove Extract and Maqui Berry extract capsule, .Whole Food Blend capsule, Turmeric extract capsule, European White Kidney Bean capsule, Saffron extract capsule, Ubiquinol with Fulvic acid complex softgel, Calcium with Hesperidin and gynostemma extract tablet, Multivitamin and mineral supplement; Dietary Supplement
Lead sponsor: Supplement Formulators, Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: HIV Infections
Interventions: ATV, Ritonavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 91 Days to 21 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2014
U.S. locations: 32
States / cities: Birmingham, Alabama • Alhambra, California • La Jolla, California + 23 more

Conditions: Adverse Childhood Experiences, Endothelial Dysfunction
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Iowa City, Iowa • Madison, Wisconsin

Conditions: Chronic Rhinitis
Interventions: Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray, Mometasone Nasal Irrigation (1 mg capsule), Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Essential Hypertension
Interventions: Allopurinol, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Autosomal Dominant Polycystic Kidney, ADPKD
Interventions: Bardoxolone methyl oral capsule, Placebo oral capsule; Drug
Lead sponsor: Biogen; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 667 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 83
States / cities: Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 69 more

Conditions: Autism
Interventions: Memantine - Extended Release (ER), Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 17
States / cities: Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more

Conditions: Multiple Myeloma
Interventions: Bortezomib, Dexamethasone, Lenalidomide, Acetaminophen, Diphenhydramine, Montelukast, Carfilzomib, Daratumumab, Autologous Stem Cell Transplant (ASCT); Drug · Biological
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 75 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Miami, Florida • Tampa, Florida • Buffalo, New York + 4 more

Conditions: Healthy Subjects
Interventions: Apremilast, Rifampin Oral Capsules, Rifampin IV Solution; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Orthopaedic Fractures
Interventions: NSAID, Gabapentinoids, placebo; Drug
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 17
States / cities: Miami, Florida • West Palm Beach, Florida • Indianapolis, Indiana + 13 more

Conditions: Schizophrenia, Psychotic Disorders
Interventions: naltrexone, placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 21 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Icalcaprant, Placebo for Icalcaprant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 33
States / cities: Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more

Conditions: Schizophrenia, Schizophrenia; Psychosis
Interventions: Xanomeline and Trospium Chloride Capsules, Placebo; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 20
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 15 more

Conditions: High Blood Pressure, Liver Transplant, Renal Function Abnormal
Interventions: Amlodipine Besylate, Chlorthalidone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Myelofibrosis, MPN - Accelerated or Blast Phase, Chric Phase MPN
Interventions: Oral THU-decitabine; Drug
Lead sponsor: John Mascarenhas; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2033
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19
Interventions: PF-07321332, Ritonavir, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 78
States / cities: Pelham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 51 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: erlotinib, sunitinib, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 18
States / cities: Birmingham, Alabama • Mobile, Alabama • Antioch, California + 13 more

Conditions: Mantle Cell Lymphoma, Lymphoma
Interventions: BR-I (bendamustine, rituximab, ibrutinib), VEN (Venetoclax); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Drug Interactions
Interventions: Proellex, CYP1A2 probe, CYP2C9 probe, CYP2C19 probe, CYP2D6 probe, CYP3A4 probe; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Diabetes Mellitus, Diabetic Macular Edema
Interventions: ASP8232, ranibizumab, Placebo, Sham intravitreal (IVT) injection; Drug · Other
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 21
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 18 more

Search by objective public record fields.

A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation

Curcumin in Kidney Transplant Recipients

Does Weight Loss Surgery and Probiotic Supplementation Lead to a "Lean" Gut Microbiota?

Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin

Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

ACEs, SIRT1, and Premature Vascular Aging in Humans

Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis

Uric Acid in Essential Hypertension in Children

A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON

Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast

Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)

Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)

Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)

Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)